Cellectis appoints Dr Andrew Scharenberg
pharmafile | July 12, 2011 | Appointment | Manufacturing and Production, Research and Development |Â Â appointment, manufacturing and production, research and developmentÂ
Paris-based genome engineering specialist Cellectis Therapeutics has appointed Dr Andrew Scharenberg as chief scientific officer.
He is an attending physician in Immunology at Seattle Children’s Hospital, and Professor of Pediatrics and Immunology at the University of Washington.
Dr Scharenberg is also a principal investigator and co-director of the Northwest Genome Engineering Consortium (NGEC), which is focused on new approaches for treating genetic diseases.
In addition, he is a cofounder and member of the Board of Director’s of Pregenen, a biotechnology spin-off from the NGEC, and a strategic partner of Cellectis.
“We are thrilled that Andrew Scharenberg has accepted the post of chief scientific officer of our therapeutic subsidiary,” said chief scientific officer of the Cellectis group Frederic Paques. “His experience and energy will push our research teams to achieve their full potential.”
Related Content

Bio-Techne opens GMP small-molecule manufacturing facility in Bristol
Bio-Techne has opened a new facility in Bristol manufacturing Good Manufacturing Practice (GMP)-grade small molecules …

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …





